Melatonin trial targets rare eye cancer with novel drug approach

Researchers are launching a major clinical trial testing whether melatonin can improve survival rates for uveal melanoma, a rare but aggressive eye cancer. If successful, the findings could expand treatment options for a disease with limited therapies and offer pharmaceutical companies a potential new market opportunity in oncology.

Originaltitel: Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study